TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Dr Reddy’s Laboratories ( (RDY) ) is now available.
On November 13, 2025, Dr. Reddy’s Laboratories announced the allotment of 7,430 equity shares to eligible employees under its Employees Stock Options Scheme, 2002. This move reflects the company’s commitment to employee engagement and retention, potentially enhancing its operational efficiency and stakeholder value.
The most recent analyst rating on (RDY) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
Dr Reddy’s Laboratories’ overall stock score is driven by strong financial performance and a reasonable valuation. However, technical analysis indicates bearish trends, and the earnings call highlights both growth opportunities and challenges, particularly in the U.S. market. The absence of significant corporate events further focuses the score on these core components.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a pharmaceutical company based in Hyderabad, India, known for producing a wide range of generic medications, active pharmaceutical ingredients, and biologics. The company is focused on providing affordable and innovative medicines to patients worldwide and is listed on major stock exchanges including BSE, NSE, and NYSE.
Average Trading Volume: 1,023,357
Technical Sentiment Signal: Hold
Current Market Cap: $11.57B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.